Comparison of Bevacizumab and Combined Low-dose Bevacizumab and Triamcinolone in Central Retinal Vein Occlusion.
10.3341/jkos.2016.57.3.438
- Author:
Byung Jae KIM
1
;
Hyun Woong KIM
;
Yong Seop HAN
;
Jong Moon PARK
;
In Young CHUNG
Author Information
1. Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Korea. in0chung@hanmail.net
- Publication Type:Original Article
- Keywords:
Central retinal vein occlusion;
Intravitreal bevacizumab injection;
Intravitreal triamcinolone injection
- MeSH:
Humans;
Intraocular Pressure;
Intravitreal Injections;
Retinal Vein*;
Triamcinolone*;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2016;57(3):438-444
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To report the effects and intraocular pressure (IOP) results of intravitreal injection of bevacizumab alone compared with intravitreal low-dose bevacizumab combined with low-dose triamcinolone injection in patients with central retinal vein occlusion. METHODS: In total, 40 eyes of 40 patients diagnosed with central retinal vein occlusion were evaluated. Of these, 20 eyes of 20 patients were injected with intravitreal bevacizumab (1.25 mg/0.05 mL), and 20 eyes of 20 patients were injected with low-dose bevacizumab (0.625 mg/0.025 mL) combined with low-dose triamcinolone (1 mg/0.025 mL). The best corrected visual acuity (BCVA), central macular thickness (CMT), and IOP of treated eyes were measured before injection and at 1 month, 2 months, and 3 months after injection. RESULTS: In both the intravitreal bevacizumab and the low-dose bevacizumab combined with low-dose triamcinolone groups, CMT decreased significantly at 1 month, 2 months, and 3 months after injection (p < 0.05). In addition, in both groups, neither IOP nor BCVA decreased significantly at 1 month, 2 months, or 3 months after injection (p > 0.05). The BCVA, IOP, and CMT at 1 month, 2 months, and 3 months after injection showed no significant differences between the intravitreal bevacizumab group and the low-dose bevacizumab combined with low-dose triamcinolone group (p > 0.05). CONCLUSIONS: The CMT of both groups decreased significantly, and BCVA of both groups increased significantly in patients with central retinal vein occlusion. Injection of low-dose intravitreal bevacizumab combined with low-dose intravitreal triamcinolone may be useful for the treatment of central retinal vein occlusion.
